ArticleAging cell2011
The telomerase activator TA-65 elongates short telomeres and increases health span of adult/old mice without increasing cancer incidence.
Article in Aging cell, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 138 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
138 citing papers in PubMed, 2 syntheses or guidelines pooled it, 339 citations in OpenAlex.
- Effects of TA-65 on telomere length, functional outcomes, and inflammation: a systematic review and meta-analysis.Cell biology and toxicology · 2025Pooled it
- Telomerase activation in the treatment of aging or degenerative diseases: a systematic review.Molecular and cellular biochemistry · 2021Pooled it
- Trial
- A Natural Product Telomerase Activator Lengthens Telomeres in Humans: A Randomized, Double Blind, and Placebo Controlled Study.Rejuvenation research · 2016Trial
- Review
- Improvement of fertility in female mice by treatment with novel telomerase-increasing compounds.Reproductive biology and endocrinology : RB&E · 2026Article
- Type 2 Diabetes From the Perspective of Telomere Biology.Endocrinology, diabetes & metabolism · 2026Review
- Cycloastragenol Derivatives Improve Tyrosine Metabolism, Regulate TLR4/NF-κB/TERT Signaling Pathways, and Inhibit MPTP Induced Neuroinflammation and PD Symptoms.CNS neuroscience & therapeutics · 2026Article
- The Use of Nutritional Interventions to Enhance Genomic Stability in Mice and Delay Aging.Nutrients · 2026Review
- Cycloastragenol Improves Fatty Acid Metabolism Through NHR-49/FAT-7 Suppression and Potent AAK-2 Activation inInternational journal of molecular sciences · 2026Article
- Mechanistic redundancy and hierarchy of aging mechanisms: implications for strategies to extend healthspan and biomarker integration.Frontiers in aging · 2026Review
- Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity.Biogerontology · 2025Article
- Targeting Telomere Shortening in Vascular Aging and Atherosclerosis: Therapeutic Promise ofJournal of cardiovascular development and disease · 2025Review
- Trajectories of cardiovascular ageing-from molecular mechanisms to clinical implementation.Cardiovascular research · 2025Review
- Natural Anti-aging Herb: Role and Potential of Astragalus membranaceus.Chinese journal of integrative medicine · 2025Review
- Review
- A promising new TERT activator: unraveling the molecular mechanisms behind its natural aging mitigation.Frontiers of medicine · 2025Article
- Astragalus Membranaceus-Can It Delay Cellular Aging?Nutrients · 2025Review
- The relationship between telomere length and aging-related diseases.Clinical and experimental medicine · 2025Review
- 37 kDa LRP::FLAG enhances telomerase activity and reduces ageing markers in vivo.Cellular and molecular life sciences : CMLS · 2025Article
78 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
Abstract
Here, we show that a small-molecule activator of telomerase (TA-65) purified from the root of Astragalus membranaceus is capable of increasing average telomere length and decreasing the percentage of critically short telomeres and of DNA damage in haploinsufficient mouse embryonic fibroblasts (MEFs) that harbor critically short telomeres and a single copy of the telomerase RNA Terc gene (G3 Terc(+/-) MEFs). Importantly, TA-65 does not cause telomere elongation or rescue DNA damage in similarly treated telomerase-deficient G3 Terc(-/-) littermate MEFs. These results indicate that TA-65 treatment results in telomerase-dependent elongation of short telomeres and rescue of associated DNA damage, thus demonstrating that TA-65 mechanism of action is through the telomerase pathway. In addition, we demonstrate that TA-65 is capable of increasing mouse telomerase reverse transcriptase levels in some mouse tissues and elongating critically short telomeres when supplemented as part of a standard diet in mice. Finally, TA-65 dietary supplementation in female mice leads to an improvement of certain health-span indicators including glucose tolerance, osteoporosis and skin fitness, without significantly increasing global cancer incidence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.